Exiqon A/S
Exiqon launches XploreRNA™ app for advanced cross-database queries

DGAP-News: Exiqon A/S /

09.05.2014 / 10:56

---------------------------------------------------------------------


Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression
analysis products, today announced the launch of its XploreRNA(TM) app for
advanced cross-database searches, easy interpretation of data and seamless
planning of experiments. 

XploreRNA(TM) allows scientists engaged in transcription analysis to scroll any
transcript, view splice sites, SNPs, and to zoom in on specific transcripts of
interest in an interactive interface. Major databases including Ensembl,
miRBase etc., have been cross-annotated to provide for all-in-one searches.
Relevant abstracts and original publications have been integrated through
PubMed. Products are automatically customized to address search results and
readily ordered. 

The body of biological data is growing exponentially which makes it challenging
for scientists to stay abreast and benefit from big data. To complicate matters
different annotations of major databases make cross-database searches time
consuming and complicate the identification of relevant genetic information,
e.g.  microRNA-mRNA interactions. XploreRNA(TM) overcomes all of these challenges,
and is the first in a series of new apps from Exiqon for scientists in both
academia and industry. 

XploreRNA(TM) enables 'on-the-fly' discussions based on cross-annotated scientific
information that is now made available at your fingertips. Results may be
easily shared and converted to studies of relevant gene expressions whether for
validation purposes or functional analysis. 

'An important value proposition for Exiqon is to guide our customers through
experimental data, to reach scientific conclusions and make decisions on how to
validate data. The XploreRNA(TM) app does all of this for our customers and
requires no prior knowledge about complicated database searches' says Henrik M.
Pfundheller, SVP, Sales and Marketing and continues 'Should our customers be
interested in conducting further experiments the XploreRNA(TM) will suggest the
relevant customized LNA(R) enhanced products  directly available for ordering'. 

XploreRNA(TM) is currently available on iOS platforms but will soon also be
available on Android and Windows platforms. 

XploreRNA(TM) can be downloaded at www.exiqon.com or the App Store:
https://itunes.apple.com/us/app/advanced-molecular-genetics/id871741048?ls=1&mt=
8 

Additional information:

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

About XploreRNA(TM)

XploreRNA(TM) cross-annotates major databases containing biological information
relevant for transcript analysis. All databases are regularly updated by
advanced text mining of the literature referenced through integrated access to
PubMed for reading of abstracts and original publications. 

XploreRNA(TM) enables searches across databases and different search terms or
identifiers can therefore be used to retrieve the same information.  More RNAs
can be identified than would be possible for databases searches that are
dependent on specific gene identifiers. XploreRNA(TM) allows for detailed analysis
of transcripts in human, mouse and rat. 

Search results are presented graphically including validated and predicted
microRNA targets as well as both disease and tissue information. 

About Exiqon

Exiqon's products are based on the proprietary LNA(R) technology. This technology
offers unique advantages for detection of microRNA biomarkers for life science
researchers, drug developers and cancer treating physicians working towards
personalizing medicine. Exiqon operates in two business areas: Exiqon Life
Sciences has established a position for itself as one of the market's leading
providers of microRNA research products for microRNA analysis in cells. Our
research products are used by academia, biotech and pharmaceutical companies
around the world to make groundbreaking discoveries about the correlation
between gene activity and the development of cancer and other diseases. Exiqon
Life Sciences is also collaborating with pharmaceutical companies in their
effort to develop new medicines based on microRNA as biological markers. Exiqon
Diagnostics collaborates with pharmaceutical and diagnostic companies to
develop novel molecular diagnostic tests for early detection of diseases which
can help physicians make treatment decisions. Exiqon is listed on the NASDAQ
OMX in Copenhagen.
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

09.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English       
Company:     Exiqon A/S    
 
 
             Denmark       
ISIN:        DK0060077758  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
267517 09.05.2014